
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is a promising company in the biotechnology sector with its novel approach to gene therapy delivery, specifically targeting mucosal tissues and other organs. With its lead candidate, detalimogene, showing potential in treating non-muscle invasive bladder cancer (NMIBC), the company has a strong near-term milestone in its complete 12-month CR readout and pre-BLA meeting in 2026. While there are questions concerning the durability and efficacy of detalimogene, enGene has a clear regulatory path with its 54% any-time CR rate and is also exploring additional options through its polidocanol bladder rinse cohort. Despite the recent decline in efficacy reported, enGene has a compelling opportunity in the NMIBC market, but uncertainty remains on the regulatory bar and the company's path forward.
Bears say
enGene Therapeutics is facing several risks as an early development-stage biopharmaceutical company. These include potential failure to demonstrate efficacy in clinical trials, delays in regulatory approvals, and competition from companies with greater resources. Additionally, the company's lead product, detalimogene, may have weaker-than-expected durability and an unclear mechanism of action, leading to a more conservative outlook for its commercial potential. With lower market share and probability of success assumptions, we believe the company's stock may struggle to reach its previous price targets.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares